The prevalence of pre-existing comorbidities, including hypertension, dyslipidemia, neuropathy, retinopathy, and chronic kidney disease, was similar between the insulin and oral agents groups, with no statistically significant differences observed (p-values ranged from 0.32 to 0.76). The gene discussed is INS; the disease is metabolic syndrome.